Fibrin Deposition in Squamous Cell Carcinomas of the Larynx and Hypopharynx

Summary

Extravascular fibrin deposition is frequently observed within and around neoplastic tissue and has been implicated in various aspects of tumor growth. The distribution of fibrin deposits was investigated in squamous cell carcinomas representing different stages of tumor progression of the larynx (n = 25) and hypopharynx (n = 9) by immunofluorescent techniques. Double and treble labelings were used to detect fibrinogen and fibrin in combination with marker antigens for tumor cells (cytokeratin), endothelial cells (von Willebrand factor), macrophages (recognized by KiM7), as well as factor XIII subunit A (FXIIIA) and tenascin (an embryonic extracellular matrix protein newly expressed during tumorigenesis). All tissue samples showed specific staining for fibrinogen/fibrin. Fibrin deposition was localized almost exclusively in the connective tissue compartment of tumors with characteristic accumulation at the interface of connective tissue and the tumorous parenchyma. In certain tumor samples showing highly invasive characteristics, fibrin deposits were observed in close association with tumor blood vessels in the tumor cell nodules. The overlapping reactions with polyclonal antibody to fibrinogen/fibrin and monoclonal antibody to fibrin indicate the activation of the coagulation cascade resulting in in situ thrombin activation and fibrin formation. Fibrin was crosslinked and stabilized by FXIIIA as revealed by urea insolubility test. Accumulation of phagocytozing macrophages detected by Ki M7 monoclonal antibody could be seen in areas of fibrin deposition. The blood coagulation factor XIIIA was detected in and around the cells labeled with Ki M7 antibody. Tenascin and fibrin deposits were found in the same localization in the tumor stroma and in association with tumor blood vessels within the tumor cell nodules. Neither fibrin nor tenascin were detected in the histologically normal tissue adjacent to tumors. The close association between fibrin deposits and macrophage accumulation strongly suggests the active participation of tumor-associated macrophages in the formation of stabilized intratumoral fibrin that facilitates tumor matrix generation and tumor angiogenesis.

• References

• 1 Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris London: New Sydenham Society; 1865. 3 94.
• 2 Sack Jr GH, Levin J, Bell W. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathologic, therapeutic features. Medicine 1977; 56: 1-27.
• 3 Harris NL, Dvorak AM, Smith J, Dvorak HF. Fibrin deposits in Hodgkin’s disease. Am J Pathol 1982; 108: 119-29.
• 4 Ádány R, Szegedi A, Ablin RJ, Muszbek L. Fibrinolysis resistant fibrin de posits in lymph nodes with Hodgkin’s disease. Thromb Haemost 1988; 60: 293-7.
• 5 Muszbek L, Ádány R. Intratumoral fibrin stabilization. In: Eicosanoids, lipid peroxidation and cancer. Nigam SK, McBrien DCH, Slater TF. eds. New York: Springer-Verlag; 1988: 339-49.
• 6 Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 69: 406-14.
• 7 Ádány R. Tumor matrix biology. CRC Press; Boca Raton, CA: 1995
• 8 Thornes RD, Edlow DW, Wood S. Inhibition of locomotion of cancer cells in vivo by anticoagulant therapy. – Effects of sodium-warfarin on V₂ cancer cells, granulocytes, lymphocytes and macrophages in rabbits. Johns Hophins Med J 1968; 123: 305-10.
• 9 Cliffton EE, Grossi CE. The rationale of anticoagulants in the treatment of cancer. J Med 1974; 5: 107-13.
• 10 Schlager SI, Dray S. Complete local tumor regression with antibody to fibrin fragment E. J Immunol 1975; 115: 976-81.
• 11 Peterson HI. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumours. Cancer Treat Rev 1977; 4: 213-33.
• 12 Donati MB, Mussoni L, Poggi A, DeGaetano G, Garattini S. Growth and metastasis of the Lewis lung carcinoma in mice defibrinated with batroxobin. Eur J Cancer 1978; 14: 343-7.
• 13 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards R, Headley E, Kim SH, O’Donnell JR, O’Dell R, Tornyos K, Kwaan HC. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981; 245: 831-5.
• 14 Carter RL. Pathology of squamous cell carcinomas of the head and neck. Curr Opin Oncol 1991; 3: 507-11.
• 15 Dreyfuss A, Clark JR. Analysis of prognostic factors in squamous cell carcinomas of the head and neck. Hematol Oncol Clin N Am 1991; 5: 701-12.
• 16 Kramp B, Sievert U. Prognostic factors in laryngeal cancer. Arch Geschwulstforsch 1989; 59: 183-9.
• 17 Cerezo L, Millan I, Torre A, Aragon G, Otero J. Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. Cancer 1992; 69: 1224-34.
• 18 Brown LF, Chester JF, Malt RA, Dvorak HF. Fibrin deposition in autochthonus syrian hamster pancreatic adenocarcinomas induced by the chemical carcinogen N-nitroso-bis(2-oxopropyl)amine. J Natl Cancer Inst 1987; 78: 979-84.
• 19 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-32.
• 20 Schlegel R, Banks-Schlegel S, Pinkus GS. Immunohistochemical localization of keratin in normal human tissues. Lab Invest 1980; 42: 91-6.
• 21 Naiem M, Gerdes J, Abdulaziz Z, Sunderland CA, Allington MJ, Stein H, Mason DY. The value of immunohistological screening in the production of monoclonal antibodies. J Immunol Methods 1982; 50: 145-60.
• 22 Kreipe H, Radzun HJ, Parwaresch MR, Haislip A, Hansmann ML. Ki-M7 monoclonal antibody specific for myelomonocytic cell lineage and macrophages in human. J Histochem Cytochem 1987; 35: 1117-26.
• 23 Kiesselbach TH, Wagner RH. Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique. Ann NY Acad Sci 1972; 202: 318-28.
• 24 Muszbek L, Ádány R, Szegedi G, Polgár J, Kávai M. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-10.
• 25 Henriksson P, Becker S, Lynch G, McDonagh J. Identification of factor XIII in human monocytes and macrophages. J Clin Invest 1985; 76: 528-34.
• 26 Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983; 43: 2796-805.
• 27 Sakakura T. Role of tenascin in cancer development. In: Tumor matrix biology. Ádány R. ed. CRC Press; Boca Raton, CA: 1995: 101-29.
• 28 Muszbek L, Laki K. Interaction of thrombin with proteins other than fibrinogen (thrombin susceptible bonds). Activation of FXIII. In: The Thrombin. Machovich R. ed. CRC Press; Boca Raton, CA: 1984: 321-42.
• 29 Sakata Y, Aoki N. Cross-linking of α₂-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
• 30 Danø K, Andreasen PA, Gondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
• 31 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
• 32 Varani J, McKeever PE, Fligiel SEG, Sitrin RG. Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions. Int J Cancer 1987; 40: 772-7.
• 33 Sitrin RG, Gyetko MR, Kole KL, McKeever P, Varani J. Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. Cancer Res 1990; 50: 4957-61.
• 34 Caccamo DV, Keohane ME, McKeever PE. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. Mod Pathol 1994; 7: 99-104.
• 35 Zacharski LR, Memoli VA, Rousseau SM, Kisiel W. Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer 1987; 60: 2675-81.
• 36 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-21.
• 37 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-82.
• 38 Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med 1981; 98: 917-28.
• 39 Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semerano N, Mantovani A, Donati MB. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-3.
• 40 Ádány R, Nemes Z, Muszbek L. Characterization of factor XIII containing macrophages in lymph nodes with Hodgkin’s disease. Br J Cancer 1987; 55: 421-6.
• 41 Ádány R, Kappelmayer J, Berényi E, Szegedi A, Fábián E, Muszbek L. Factors of the extrinsic pathway of blood coagulation in tumour associated macrophages. Thromb Haemost 1989; 62: 850-5.
• 42 Ornstein DL, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 1991; 68: 1061-7.
• 43 Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and nonmalignant lymphoid tissue. J Lab Clin Med 1992; 119: 124-31.
• 44 Ádány R, Belkin A, Vasilevskaya T, Muszbek L. Identification of blood coagulation factor XIII in human peritoneal macrophages. Eur J Cell Biol 1985; 38: 171-3.
• 45 Ádány R, Nemes Z, Thomázy V, Muszbek L. Identification of factor XIII in macrophages invading lymph nodes with Hodgkin’s disease. In: Haemostasis and Cancer. Muszbek L. ed. CRC Press; Boca Raton, CA: 1987: 115-24.
• 46 Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J. Factor XIII is synthetized and expressed on the surface of U937 cells and alveolar macrophages. Blood 1987; 69: 778-85.
• 47 Roth WJ, Fleit HB, Chung SI, Janoff A. Characterization of two distinct transglutaminases of murine bone marrow-derived macrophages. J Leuk Biol 1987; 42: 9-20.
• 48 Ádány R, Kappelmayer J, Muszbek L. Expression of FXIII subunit a in different types of human macrophages. In: The biology of phagocytes in health and disease. Mauri C, Rizzo SC, Ricevuti G. eds. Adv Biosci 1987; 66: 323-33.
• 49 Ádány R, Kiss A, Muszbek L. Factor XIII: a marker of mono- and megaka riocytopoesis. Br J Haematol 1987; 67: 167-72.
• 50 Bárdos H, Molnár P, Csécsei Gy, Ádány R. Fibrin deposition in primary and metastatic human brain tumours. Blood Coag Fibrinol 1996; 7: 536-48.
• 51 Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-5.
• 52 Levy AP, Tamargo R, Brem H, Nathans D. An endothelial cell growth factor from the mouse neuroblastoma cell line NB41. Growth Factors 1989; 2: 9-19.
• 53 Senger DR, Connoly DT, Van DeWater L, Feder J, Dvorak HF. Purification and NH₂-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1174-8.
• 54 Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-35.
• 55 Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994; 59: 520-9.
• 56 Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
• 57 Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
• 58 Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
• 59 Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head end neck carcinoma: expression and prognostic significance. Mod Pathol 1997; 10: 1128-33.
• 60 Zagzag D, Friedlander DR, Dosik J, Chikramane S, Chan W, Greco MA, Allen JC, Dorovni-Zis K, Grumet M. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996; 56: 182-9.
• 61 McComb RD, Bigner DD. Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. J Neuro-Oncol 1985; 3: 181-6.
• 62 Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawa T. Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol 1993; 85: 481-7.
• 63 Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995; 55: 907-14.
• 64 Olander JV, Bremer ME, Marase JC, Feder J. Fibrin-enhanced endothelial cell organization. J Cell Physiol 1985; 125: 1-9.
• 65 Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987; 57: 673-86.